TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT06733051

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing Golidocitinib and Benmelstobart for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Golidocitinib (DRUG): 150 mg, administered once daily from Day 1 to Day 21 (D1-D21) | Benmelstobart (DRUG): 1200 mg, administered on Day 1 (D1) of every cycle

Drugs / treatments
Golidocitinib, Benmelstobart
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

NCT06733051

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is testing Golidocitinib and Benmelstobart for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Golidocitinib (DRUG): 150 mg, administered once daily from Day 1 to Day 21 (D1-D21) | Benmelstobart (DRUG): 1200 mg, administered on Day 1 (D1) of every cycle

Drugs / treatments: Golidocitinib, Benmelstobart

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 47 patients

Primary endpoint: Objective response rate(ORR)

Ages: 18 Years to —

Start date: 2024-01-27 | Est. completion: 2028-12

Locations

0 US sites · 2 total

Contact

Qingqing Cai, MD. PhD. | caiqq@sysucc.org.cn | 0086-20-87342823

Sponsor: Sun Yat-sen University (OTHER)

Tags

ENKTL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06733051

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.